OREANDA-NEWS. September 15, 2016. IMS Health Holdings, Inc. (NYSE:IMS) today announced the pricing of its
offering of \\$1.75 billion equivalent in gross proceeds of senior notes,
consisting of \\$1.05 billion of U.S. Dollar notes and €625 million of
Euro notes to be issued by its wholly owned subsidiary, IMS Health
Incorporated. The offering was upsized from the previously announced
\\$1.5 billion equivalent aggregate principal amount. The net proceeds
from the notes offering (together with proceeds from additional term
loans and other available cash) will primarily be used to extinguish
certain of the issuer’s and Quintiles’ existing indebtedness in
connection with the previously announced proposed merger between IMS
Health and Quintiles.
The \\$1.05 billion U.S. Dollar notes will bear interest at a rate of 5.0%
and will pay interest semi-annually in arrears on April 15 and October
15 of each year beginning on April 15, 2017. The U.S. Dollar notes will
mature on October 15, 2026.
The €625 million Euro notes will bear interest at a rate of 3.5% and
will pay interest semi-annually in arrears on April 15 and October 15 of
each year beginning on April 15, 2017. The Euro notes will mature on
October 15, 2024.
Certain statements in this press release are forward-looking statements.
These statements involve a number of risks, uncertainties and other
factors including the failure to consummate the notes offering and
potential changes in market conditions that could cause actual results
to differ materially.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the notes. The notes to be offered have
not been, and will not be, registered under the Securities Act of 1933
and may not be offered or sold in the United States absent registration
or an applicable exemption from the registration requirements of the
Securities Act of 1933. The notes are being offered only to qualified
institutional buyers in the United States in reliance on Rule 144A under
the Securities Act of 1933 and outside the United States only to
non-U.S. investors pursuant to Regulation S.
About IMS Health
IMS Health (NYSE:IMS) is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our 7,000
services experts connect configurable SaaS applications to 15+ petabytes
of complex healthcare data in the IMS One™ cloud platform, delivering
unique insights into diseases, treatments, costs and outcomes. The
company’s 15,000 employees blend global consistency and local market
knowledge across 100 countries to help clients run their operations more
efficiently. Customers include pharmaceutical, consumer health and
medical device manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial
community.
As a global leader in protecting individual patient privacy, IMS Health
uses anonymous healthcare data to deliver critical, real-world disease
and treatment insights. These insights help biotech and pharmaceutical
companies, medical researchers, government agencies, payers and other
healthcare stakeholders to identify unmet treatment needs and understand
the effectiveness and value of pharmaceutical products in improving
overall health outcomes. Additional information is available at www.imshealth.com.
About Quintiles
Quintiles (NYSE:Q) helps biopharma and other healthcare companies
improve their probability of success by connecting insights from our
deep scientific, therapeutic and analytics expertise with superior
delivery for better outcomes. From advisory through operations,
Quintiles is the world’s largest provider of product development and
integrated healthcare services, including commercial and observational
solutions. Conducting operations in approximately 100 countries,
Quintiles is a member of the Fortune 500 and has been named to Fortune’s
list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Important Information about the Transaction and Where to Find It
In connection with the proposed transaction, IMS Health and Quintiles
have filed documents with the SEC, including the filing by Quintiles of
a registration statement on Form S-4 that includes a joint proxy
statement that also constitutes a prospectus of Quintiles. The
registration statement, as amended, was declared effective on August 15,
2016 by the SEC. Quintiles filed the definitive joint proxy
statement/prospectus with the SEC on August 16, 2016. On August 19,
2016, each of IMS Health and Quintiles mailed that document to their
respective shareholders and may also file other documents with the SEC
regarding the proposed transaction. This document is not a substitute
for the joint proxy statement/prospectus or registration statement or
any other document which IMS Health or Quintiles may file with the SEC. Investors
and security holders of IMS Health and Quintiles are urged to read the
registration statement, the joint proxy statement/prospectus and any
other relevant documents, as well as any amendments or supplements to
these documents, carefully and in their entirety when they become
available because they will contain important information. Investors
and security holders may obtain free copies of the registration
statement and the joint proxy statement/prospectus and other documents
filed with the SEC by IMS Health and Quintiles through the web site
maintained by the SEC at www.sec.gov
or by contacting the investor relations department of IMS Health or
Quintiles at the following:
Комментарии